Lv63
2996 积分 2022-02-25 加入
Tumour mutational burden: clinical utility, challenges and emerging improvements
4小时前
已完结
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
6小时前
已完结
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
22小时前
已完结
TMB or not TMB as a biomarker: That is the question
22小时前
已完结
Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-high/Mismatch Repair Deficient Advanced Solid Tumors: KEYNOTE-158 Final Analysis
22小时前
已完结
Adaptive increase in sample size when interim results are promising: A practical guide with examples
8天前
已完结
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
2个月前
已完结
APACHE II-A Severity of Disease Classification System
3个月前
已关闭
APACHE II-A Severity of Disease Classification System
3个月前
已完结
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
4个月前
已完结
Synthesis and Cytotoxic Activity of Combretastatin A-4 and 2,3-Diphenyl-2H-indazole Hybrids
皖公网安备34019202002308
